FDA granted Breakthrough Device Designation for CartiHeal’s Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints.
The program is intended to help patients receive more timely access to these medical devices by expediting their development, assessment and review by FDA.
A pivotal Investigational Device Exemption clinical study underway is designed to evaluate superiority of the Agili-C implant’s superiority vs. microfracture and debridement, the current standard of care. Final study results are expected next year.
“We are extremely pleased that FDA granted the Agili-C implant Breakthrough Device Designation,” said Nir Altschuler, CartiHeal’s Founder & CEO. “We look forward to working closely with FDA to expedite Agili-C’s review process, once the final IDE study results will be available, in order to provide a promising treatment for millions of patients who suffer from cartilage defects and currently lack good treatment options.”
FDA granted Breakthrough Device Designation for CartiHeal's Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints.
The program is intended to help patients receive more timely access to these medical devices by expediting their development, assessment and review by FDA.
A pivotal...
FDA granted Breakthrough Device Designation for CartiHeal’s Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints.
The program is intended to help patients receive more timely access to these medical devices by expediting their development, assessment and review by FDA.
A pivotal Investigational Device Exemption clinical study underway is designed to evaluate superiority of the Agili-C implant’s superiority vs. microfracture and debridement, the current standard of care. Final study results are expected next year.
“We are extremely pleased that FDA granted the Agili-C implant Breakthrough Device Designation,” said Nir Altschuler, CartiHeal’s Founder & CEO. “We look forward to working closely with FDA to expedite Agili-C’s review process, once the final IDE study results will be available, in order to provide a promising treatment for millions of patients who suffer from cartilage defects and currently lack good treatment options.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
